Type-Specific Human Papillomavirus Biological Features: Validated Model-Based Estimates

被引:24
作者
Baussano, Iacopo [1 ]
Elfstrom, K. Miriam [2 ]
Lazzarato, Fulvio [3 ]
Gillio-Tos, Anna [3 ]
De Marco, Laura [3 ]
Carozzi, Francesca [4 ]
Del Mistro, Annarosa [5 ]
Dillner, Joakim [2 ]
Franceschi, Silvia [1 ]
Ronco, Guglielmo [6 ]
机构
[1] Int Agcy Res Canc, F-69372 Lyon, France
[2] Karolinska Inst, Dept Med Epidemiol & Biostat, Stockholm, Sweden
[3] Univ Turin, Dept Med Sci, Canc Epidemiol Unit, Turin, Italy
[4] Inst Canc Study & Prevent ISPO, Florence, Italy
[5] Venetian Oncol Inst IOV, Padua, Italy
[6] Ctr Canc Prevent, Canc Epidemiol Unit, Turin, Italy
来源
PLOS ONE | 2013年 / 8卷 / 11期
基金
比尔及梅琳达.盖茨基金会;
关键词
COST-EFFECTIVENESS ANALYSIS; CERVICAL-CANCER; GLOBAL BURDEN; HPV TYPES; VACCINATION; IMPACT; WOMEN; INFECTIONS; TRANSMISSION; RISK;
D O I
10.1371/journal.pone.0081171
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Infection with high-risk (hr) human papillomavirus (HPV) is considered the necessary cause of cervical cancer. Vaccination against HPV16 and 18 types, which are responsible of about 75% of cervical cancer worldwide, is expected to have a major global impact on cervical cancer occurrence. Valid estimates of the parameters that regulate the natural history of hrHPV infections are crucial to draw reliable projections of the impact of vaccination. We devised a mathematical model to estimate the probability of infection transmission, the rate of clearance, and the patterns of immune response following the clearance of infection of 13 hrHPV types. To test the validity of our estimates, we fitted the same transmission model to two large independent datasets from Italy and Sweden and assessed finding consistency. The two populations, both unvaccinated, differed substantially by sexual behaviour, age distribution, and study setting (screening for cervical cancer or Chlamydia trachomatis infection). Estimated transmission probability of hrHPV types (80% for HPV16, 73%-82% for HPV18, and above 50% for most other types); clearance rates decreasing as a function of time since infection; and partial protection against re-infection with the same hrHPV type (approximately 20% for HPV16 and 50% for the other types) were similar in the two countries. The model could accurately predict the HPV16 prevalence observed in Italy among women who were not infected three years before. In conclusion, our models inform on biological parameters that cannot at the moment be measured directly from any empirical data but are essential to forecast the impact of HPV vaccination programmes.
引用
收藏
页数:10
相关论文
共 50 条
  • [1] Epidemiology of HPV 16 and cervical cancer in Finland and the potential impact of vaccination: Mathematical modelling analyses
    Barnabas, Ruanne V.
    Laukkanen, Paivi
    Koskela, Pentti
    Kontula, Osmo
    Lehtinen, Matti
    Garnett, Geoff P.
    [J]. PLOS MEDICINE, 2006, 3 (05) : 624 - 632
  • [2] Modelling patterns of clearance of HPV-16 infection and vaccination efficacy
    Baussano, Iacopo
    Garnett, Geoff
    Segnan, Nereo
    Ronco, Guglielmo
    Vineis, Paolo
    [J]. VACCINE, 2011, 29 (06) : 1270 - 1277
  • [3] HPV-16 infection and cervical cancer: Modeling the influence of duration of infection and precancerous lesions
    Baussano, Iacopo
    Ronco, Guglielmo
    Segnan, Nereo
    French, Katherine
    Vineis, Paolo
    Garnett, Geoff P.
    [J]. EPIDEMICS, 2010, 2 (01) : 21 - 28
  • [4] Model-Based Estimation of Viral Transmissibility and Infection-Induced Resistance From the Age-Dependent Prevalence of Infection for 14 High-Risk Types of Human Papillomavirus
    Bogaards, Johannes A.
    Xiridou, Maria
    Coupe, Veerle M. H.
    Meijer, Chris J. L. M.
    Wallinga, Jacco
    Berkhof, Johannes
    [J]. AMERICAN JOURNAL OF EPIDEMIOLOGY, 2010, 171 (07) : 817 - 825
  • [5] Genital Transmission of Human Papillomavirus in Recently Formed Heterosexual Couples
    Burchell, Ann N.
    Coutlee, Francois
    Tellier, Pierre-Paul
    Hanley, James
    Franco, Eduardo L.
    [J]. JOURNAL OF INFECTIOUS DISEASES, 2011, 204 (11) : 1723 - 1729
  • [6] Human Papillomavirus Infections Among Couples in New Sexual Relationships
    Burchell, Ann N.
    Tellier, Pierre-Paul
    Hanley, James
    Coutlee, Francois
    Franco, Eduardo L.
    [J]. EPIDEMIOLOGY, 2010, 21 (01) : 31 - 37
  • [7] Concurrent infections with multiple human papillomavirus (HPV) types in the New Technologies for Cervical Cancer (NTCC) screening study
    Carozzi, Francesca
    Ronco, Guglielmo
    Gillio-Tos, Anna
    De Marco, Laura
    Del Mistro, Annarosa
    Girlando, Salvatore
    Franceschi, Silvia
    Plummer, Martyn
    Vaccarella, Salvatore
    [J]. EUROPEAN JOURNAL OF CANCER, 2012, 48 (11) : 1633 - 1637
  • [8] End-of-study safety, immunogenicity, and efficacy of quadrivalent HPV (types 6, 11, 16, 18) recombinant vaccine in adult women 24-45 years of age
    Castellsague, X.
    Munoz, N.
    Pitisuttithum, P.
    Ferris, D.
    Monsonego, J.
    Ault, K.
    Luna, J.
    Myers, E.
    Mallary, S.
    Bautista, O. M.
    Bryan, J.
    Vuocolo, S.
    Haupt, R. M.
    Saah, A.
    [J]. BRITISH JOURNAL OF CANCER, 2011, 105 (01) : 28 - 37
  • [9] Transmission dynamic modelling of the impact of human papillomavirus vaccination in the United Kingdom
    Choi, Yoon Hong
    Jit, Mark
    Gay, Nigel
    Cox, Andrew
    Garnett, Geoff P.
    Edmunds, William John
    [J]. VACCINE, 2010, 28 (24) : 4091 - 4102
  • [10] Mathematical models for predicting the epidemiologic and economic impact of vaccination against human papillomavirus infection and disease
    Dasbach, Erik J.
    Elbasha, Elarnin H.
    Insinga, Ralph P.
    [J]. EPIDEMIOLOGIC REVIEWS, 2006, 28 : 88 - 100